• 1
    Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25e146.
  • 2
    Qureshi AI, Suri MFK, Kirmani JF, et al. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit. 2005;11:CR403CR409.
  • 3
    Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 4
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937952.
  • 5
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 6
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:21212158.
  • 7
    Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243256.
  • 8
    Masson S, Solomon S, Angelici L, et al. Plasma renin activity retains a strong prognostic value in patients with chronic HF, independent of ACE inhibitor or beta-blocker therapy. Data from the Valsartan Heart Failure (Val-HeFT) trial. Eur Heart J. 2009;30(suppl):163 (1099).
  • 9
    Verma S, Gupta MK, Holmes DT, et al. Plasma renin activity is associated with increased cardiovascular events and mortality in the HOPE study. Circulation. 2009;18 (suppl ):S453 (1134).
  • 10
    Bair TL, May HT, Prescott MF, et al. Association between baseline levels of plasma renin activity and risk of cardiovascular events. J Am Coll Cardiol. 2009:A383 (Abstract 1028–1012).
  • 11
    Bair TL, May HT, Prescott MF, et al. Association between baseline plasma renin activity and risk of cardiovascular events in coronary artery disease patients. J Clin Hypertens. 2009;11 (suppl A):A88 (Abstract P-176).
  • 12
    May HT, Prescott MF, Anderson JL, et al. Association between baseline levels of plasma renin activity and risk of cardiovascular events in women with coronary heart disease. Circulation. 2009;120:S453 (1133).
  • 13
    Muhlestein JB, Bair TL, May HT, et al. Association between baseline plasma renin activity and risk of clinical events in patients with diabetes and coronary artery disease. Diabetes. 2009;58:A26.
  • 14
    Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs. 2007;67:17671792.
  • 15
    Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217226.
  • 16
    Weycker D, Edelsberg J, Vincze G, et al. Blood pressure control in patients initiating antihypertensive therapy. Ann Pharmacother. 2008;42:169176.
  • 17
    Townsend R, Forker A, Rumpelt P, et al. Initial combination therapy with aliskiren/hydrochlorothiazide is more effective than amlodipine in patients with stage 2 systolic hypertension and diabetes mellitus. J Clin Hypertens. 2010;12 (suppl):534 (LB-PO-03).
  • 18
    Whaley-Connell A, Sowers JR, Purkayastha D, et al. Combination therapy with aliskiren and hydrochlorothiazide decreases plasma renin activity and oxidative stress versus ramipril while reducing blood pressure in obese patients with stage 2 hypertension. J Clin Hypertens. 2010;12 (suppl 1):A46A47 (Abstract PO-66).
  • 19
    Basile J, Babazadeh S, Lillestol M, et al. First-line aliskiren/hydrochlorothiazide combination treatment lowers BP more effectively than hydrochlorothiazide alone in older patients with stage 2 hypertension (ACTION study). J Clin Hypertens. 2010;12 (suppl 1):A22 (Abstract PO-11).
  • 20
    Franklin SS, Neutel JM. Irbesartan/HCTZ as initial treatment for patients with isolated systolic hypertension. J Clin Hypertens. 2009;11(4 suppl A):A27 (Abstract P-28).
  • 21
    Neutel JM, Littlejohn T III, Shojaee A, et al. Efficacy of olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ) in elderly (?65 years) patients (PTS) based on baseline (BL) hypertension (HTN) stage 1 and 2. J Clin Hypertens. 2009;11(4 suppl A):A131 (Abstract P-284).
  • 22
    Neutel J, Punzi H, Xu J, et al. Blood pressure (BP)-lowering efficacy of olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) vs benazepril (BN) + amlodipine (AML) therapy in black patients (pts) with stage 2 hypertension (HT). J Hypertens. 2008;26(suppl 1):S455 (Abstract PS432/WED/416).
  • 23
    Izzo JL Jr, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich). 2007;9:3644.
  • 24
    Lacourciere Y, Wright JT Jr, Samuel R, et al. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press Monit. 2009;14:112120.
  • 25
    Duprez DA, Munger MA, Botha J, et al. Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial. J Hum Hypertens. 2009: doi: 10.1038/jhh.2009.1107.
  • 26
    Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol. 1971;27:335346.
  • 27
    Black HR. The paradigm has shifted to systolic blood pressure. J Hum Hypertens. 2004;18(suppl 2):S3S7.
  • 28
    Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371:22192221.
  • 29
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:20222031.
  • 30
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:20492051.
  • 31
    ALLHAT. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 32
    Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:24172428.
  • 33
    Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:8086.
  • 34
    Staessen JA, Thijisq L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22:847857.
  • 35
    Andersen K, Weinberger MH, Constance CM, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10:157167.